BRIEF REPORT

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

Alanna C. McEneny-King · Jonathan P. R. Monteleone ·

Shamsah D. Kazani · Stephan R. Ortiz

ABSTRACT

Introduction: Terminal complement amplification is hypothesized to be a key contributor to the clinical manifestations of severe coronavirus disease 2019 (COVID-19). Ravulizumab, a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, is being evaluated as a treatment for COVID-19-related severe pneumonia, acute lung injury, and acute respiratory distress syndrome in an ongoing phase 3 randomized controlled trial (ALXN1210-COV-305). To address the overactivation of terminal complement in severe COVID-19 compared to the diseases in which ravulizumab is currently approved, a modified dosing regimen was adopted. This analysis evaluates preliminary pharmacokinetic/ pharmacodynamic data to confirm the modified dosing regimen.

Methods: Weight-based ravulizumab doses were administered on days 1, 5, 10, and 15. Serum levels of ravulizumab and free C5 were measured before and after administration of ravulizumab and any time on day 22. Free C5 levels $< 0.5\ \mu g/mL$ indicate complete C5 inhibition. The pharmacokinetic target was defined as ravulizumab concentrations at the end of the dosing interval $> 175\ \mu g/mL$, the concentration above which C5 is completely inhibited.

Results: Twenty-two patients were included in this evaluation. At baseline, mean C5 concentration was $240 \pm 67\ \mu g/mL$. In all patients and at all individual timepoints after the first dose was administered, ravulizumab concentrations remained $> 175\ \mu g/mL$ and free C5 concentrations remained $< 0.5\ \mu g/mL$.

Conclusion: High levels of baseline C5 observed in patients with severe COVID-19 contribute to the growing body of evidence that suggests this disease is marked by amplification of terminal complement activation. Data from this preliminary pharmacokinetic/pharmacodynamic evaluation of 22 patients with severe COVID-19 show that the modified ravulizumab dosing regimen achieved immediate and complete terminal complement inhibition, which can be sustained for up to 22 days. These data support the continued use of this dosage regimen in the ongoing phase 3 study.

A. C. McEneny-King · S. R. Ortiz (✉)
Clinical Development and Translational Sciences,
Clinical Pharmacology, Alexion Pharmaceuticals,
Boston, MA, USA
e-mail: Stephan.Ortiz@alexion.com

J. P. R. Monteleone
Clinical Development and Translational Sciences,
Pharmacometrics, Alexion Pharmaceuticals, Boston,
MA, USA

S. D. Kazani
Clinical Development and Translational Sciences,
Alexion Pharmaceuticals, Boston, MA, USA

PLAIN LANGUAGE SUMMARY

While many people have no or mild COVID-19 symptoms, a small number of people become very sick and require hospitalization in intensive care units. One part of their immune system, known as complement, overreacts and attacks the lungs and other organs. Researchers are looking for a way to keep the immune system from attacking the body instead of protecting it. Ravulizumab is a medication currently used to do this in other diseases. Ravulizumab is being studied to see if it can reduce the destructive and deadly effects of the coronavirus infection. In this evaluation, ravulizumab effectively reduced complement in patients with severe COVID-19.

Key Summary Points

Why carry out this study?

There is an urgent clinical need for approved treatments that target immune system dysregulation and consequent amplification of the terminal complement pathway in patients with severe acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).

Ravulizumab, a humanized monoclonal antibody that binds with high affinity to C5 and inhibits terminal complement activation, is being evaluated in an ongoing phase 3 randomized controlled trial (ALXN1210-COV-305) in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome.

This evaluation assesses whether the modified dosing regimen selected to mitigate the amplification of terminal complement results in immediate and complete terminal complement inhibition.

What was learned from the study?

The high baseline serum C5 levels observed in patients with severe COVID-19 contributes to the growing body of evidence that suggests this disease is marked by amplification of terminal complement activation.

This evaluation of preliminary pharmacokinetic/pharmacodynamic data from 22 patients with severe COVID-19 shows that the modified ravulizumab dosing regimen achieved immediate and complete terminal complement inhibition for up to 22 days and supports the continued use of the dosage regimen in the ongoing phase 3 study.

DIGITAL FEATURES

This article is published with digital features, including a summary slide and plain language summary, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.14113445.

INTRODUCTION

Severe coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is characterized by acute respiratory distress syndrome in approximately one-third of hospitalized patients [1]. Though the pathophysiology of the severe disease is still under investigation, it appears to be characterized by a dysregulation of the host immune response, by a proinflammatory, hypercoagulable state, and potentially by alterations in the complement system [2–5]. In particular, data collected from small groups of patients have shown that elements of the terminal complement pathway are amplified beyond what is expected in a typical immune response to viral infections [6–13]. Complement component C5a is an anaphylatoxin that recruits neutrophils, amplifies NETosis, and induces the prothrombotic state [2]. The membrane attack complex (C5b-9) directly promotes platelet adhesion and coagulation and can cause endothelial inflammation and microvascular injury [2]. These C5 activation products are elevated in patients with severe COVID-19 and increase with disease severity [2, 5–13].

While these data do not allow us to determine whether complement overactivation is a marker or a driver of disease progression, a small body of evidence may suggest a causal link. Mouse models of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have shown that compared to wild-type controls, complement-deficient mice infected with SARS-CoV or MERS-CoV develop less respiratory dysfunction, less lung tissue damage, and lower levels of tissue and systemic inflammation [14, 15]. In addition, case reports and one small,

proof-of-concept, compassionate-use study suggest that inhibition of terminal complement at C5, the precursor to C5a and C5b-9, may interrupt tissue-damaging feedback loops and improve clinical outcomes and prognosis [6, 16–18]. Together these data suggest that C5 inhibition may represent a potential therapeutic target for severe COVID-19.

Ravulizumab (Ultomiris^{TM}; Alexion Pharmaceuticals, Inc., Boston, MA, USA) is a humanized monoclonal antibody that binds with high affinity to C5 [19] and inhibits its cleavage into C5a and C5b. Ravulizumab is efficacious and safe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two diseases in which complement levels are moderately elevated [20–22]. In these immunomodulatory diseases, ravulizumab inhibits the terminal complement pathway; and as a result, pathological sequelae, which develop from uncontrolled terminal complement activation, such as cell death and tissue damage, are obviated.

To determine whether treatment with ravulizumab can improve outcomes in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome, a phase 3, open-label randomized controlled trial (ALXN1210-COV-305; NCT04369469) is underway [23]. As terminal complement may be more highly amplified in patients with severe COVID-19 than in patients with PNH or aHUS, [6, 16, 20–22], a modified dosing regimen was adopted. This preliminary pharmacokinetic (PK)/pharmacodynamic (PD) evaluation was undertaken to document levels of C5 in patients with severe COVID-19 and to determine if the modified dosing regimen provides immediate and complete C5 inhibition in these patients [23]. The protocol-specified outcomes will be the subject of a separate analysis.

METHODS

A detailed protocol description of ALXN1210-COV-305 has been published [23]. In brief, ALXN1210-COV-305 is an ongoing phase 3, open-label randomized controlled trial. Patients with a confirmed diagnosis of SARS-CoV-2

infection requiring hospitalization and mechanical ventilation (invasive or non-invasive) due to COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome were enrolled. Patients were excluded if they were not expected to survive for more than 24 h; if they had been on invasive mechanical ventilation with intubation for more than 48 h prior to screening; if they had severe pre-existing cardiac disease or an unresolved *Neisseria meningitidis* infection; or if they were under current treatment with a complement inhibitor, under intravenous immunoglobulin treatment within 4 weeks prior to randomization, or under current or prior (previous 30 days) treatment with an investigational therapy. Investigational therapies and antiviral therapies (such as remdesivir) were allowed if they were received as part of best supportive care (BSC) through an expanded access protocol or emergency approval for the treatment of COVID-19.

Patients were randomized to BSC or ravulizumab + BSC [20, 23]. The modified dosing schedule was designed to accommodate the expected higher baseline levels of C5, to sustain serum levels of ravulizumab, and to maintain C5 inhibition until day 29 [23]. These doses were based on dose simulations performed using a ravulizumab population PK model with an additional modification to accommodate the suspected faster anti-C5 antibody clearance in diseases that severely activate the terminal complement pathway. Weight-based ravulizumab doses were administered on days 1, 5, 10, and 15. On day 1, patients were administered the standard dose of ravulizumab: 2400 mg, 2700 mg, or 3000 mg if they weighed ≥ 40 to < 60 kg, 60 to < 100 kg, or ≥ 100 kg, respectively. Additional doses that are not approved for PNH and aHUS [20] were administered on days 5 and 10; patients were administered 600 mg if they weighed < 60 kg and 900 mg if they weighed ≥ 60 kg. On day 15, all patients were administered ravulizumab 900 mg, a modified dose that was selected to sustain serum levels of ravulizumab and maintain C5 inhibition until day 29 [23].

This PK/PD evaluation included patients randomized to the ravulizumab + BSC group. The cutoff for patient inclusion was predefined as the point at which the first 10 patients in the ravulizumab + BSC group had received the day 15 dose. Patients who had received at least one dose of ravulizumab at the time of cutoff were included in the analysis. Data from patients who withdrew from treatment were included until the time of withdrawal. Data up to the day 29 timepoint were included.

Blood samples were collected at baseline, before and after administration of each ravulizumab dose on days 1, 5, 10, and 15, and any time on day 22 and day 29. Assays used to measure serum ravulizumab levels and serum free C5 were performed as previously described [21]. Free C5 levels < 0.5 μg/mL indicate complete C5 inhibition (target PD threshold) [20]. A ravulizumab concentration at the end of the dosing interval (Ctrough) > 175 μg/mL indicates a near maximal PD effect (target PK threshold) [24].

Statistical analyses were descriptive. No sample size calculations were performed for this preliminary PK/PD evaluation. Data for missing timepoints were not imputed.

Compliance with Ethics Guidelines

Study ALXN1210-COV-305 is ongoing and is being conducted in accordance with the protocol; all applicable government regulations; the consensus ethical principles derived from international guidelines including the Declaration of Helsinki 1964, and its later amendments; the Council for International Organizations of Medical Sciences International Ethical Guidelines; and applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines. Ethics Committee approval was obtained from the Western Institutional Review Board ([IRB] central IRB tracking number, 20201059; work order number, 1-1297217-1; date of approval, 23 April 2020) and from available local IRBs (local IRB not available for two sites). Patients or their legal representative provided written informed consent. If the patient and legal representative were unable to provide informed consent and if local regulations allowed it, exceptions could be granted

Table 1 Demographics and baseline clinical characteristics

Characteristic	Ravulizumab + BSC N = 22
Male, n (%)	12 (54.5)
Age in years	
Mean ± SD	62 ± 11
Median (min, max)	66 (39, 77)
Age by category, n (%)	
< 50 years	3 (13.6)
50 to < 70 years	12 (54.5)
≥ 70 years	7 (31.8)
Weight in kg	
Mean ± SD	94.8 ± 22.7
Median (min, max)	87.2 (63.5, 160.0)
Weight by category, n (%)	
≥ 40 to < 60 kg	0
≥ 60 to < 100 kg	14 (63.6)
≥ 100 kg	8 (36.4)
Country, n (%)	
GBR	4 (18.2)
USA	18 (81.8)
Race, n (%)	
White	10 (45.5)
Black or African American	6 (27.3)
Asian	2 (9.1)
Other	1 (4.5)
Unknown	3 (13.6)
Medical conditions[a], n (%)	
Diabetes mellitus	11 (50.0)
Hypertension	10 (45.5)
Hyperlipidemia	8 (36.4)
Obesity[b]	6 (27.3)
Depression	4 (18.2)
Drug hypersensitivity	4 (18.2)
Gastroesophageal reflux disease	4 (18.2)
Asthma	3 (13.6)
Chronic kidney disease	3 (13.6)
Hyperglycemia	3 (13.6)
Hypokalemia	3 (13.6)
Myocardial infarction	3 (13.6)
Sleep apnea syndrome	3 (13.6)

BSC best supportive care, *GBR* Great Britain, *min* minimum, *max* maximum, *SD* standard deviation, *USA* United States of America

[a] Current or past non-acute comorbidities present in > 10% of patients

[b] Per physician assessment as many patients were proned and height was not measured

per the judgement of the investigator or designee. Written certification from the investigator and a physician who was not involved with the research was necessary and needed to be submitted to the IRB (local and central)/independent ethics committee within 5 working days of administration of the initial dose.

RESULTS

At cutoff, 22 patients had been randomized to ravulizumab + BSC and had received at least one dose of ravulizumab. Fifty-five percent of patients were male (Table 1). At baseline, median age was 66 years (range 39–77 years). Median weight was 87.2 kg (range 63.5–160.0 kg); eight patients weighed ≥ 100 kg. The most common comorbidities were diabetes mellitus (50% of patients), hypertension (46%), hyperlipidemia (36%), and obesity (27%).

At baseline, the mean (± standard deviation) C5 concentration was 240 ± 67 µg/mL (range 106–343 µg/mL). Three patients had C5 levels < 150 µg/mL. All other patients (86%) had C5 levels > 190 µg/mL.

At cutoff, the number of patients who had received ravulizumab at the day 1, 5, 10, and 15 timepoints was 22, 16, 12, and 10, respectively. Three patients reached the day 22 timepoint and one patient reached the day 29 timepoint. The latter patient was excluded from the day 15, day 22, and day 29 PK/PD analysis after receiving multiple packed red blood cell transfusions starting on day 12. Thus, only two patients were included in the day 22 analysis and no patients were evaluable at day 29.

Administration of the first dose of ravulizumab increased serum ravulizumab levels above the target PK threshold of 175 µg/mL in all patients (Fig. 1a). Serum ravulizumab concentrations remained above 175 µg/mL in all patients and at all measured timepoints up to day 22. For all patients, serum free C5 concentrations dropped below 0.5 µg/mL (the target threshold for complete terminal complement inhibition) after administration of the first dose of ravulizumab (Fig. 1b). All individual serum free C5 levels measured until day 22 remained below 0.5 µg/mL.

Fig. 1 Ravulizumab and free C5 concentrations over time. **a** Mean (± standard deviation) serum ravulizumab concentrations; **b** serum free C5 concentrations. Serum ravulizumab and free C5 concentrations were measured before and after ravulizumab was administered on study days 1, 5, 10, and 15, and any time on day 22. Complete terminal complement inhibition (PD threshold) was defined as serum free C5 levels < 0.5 µg/mL [20]. The PK threshold for maintaining complete terminal complement inhibition was defined as a serum ravulizumab concentration > 175 µg/mL [24]. [a]n = 13 pre-dose; one patient withdrew after the day 10 pre-dose blood draw but prior to receiving the day 10 ravulizumab dose. In **b**, the top and the bottom of the box correspond to the 75th and 25th percentiles, respectively. The whiskers represent 1.5 times the interquartile range (75th percentile–25th percentile). *PK* pharmacokinetic, *PD* pharmacodynamic

DISCUSSION

As terminal complement pathway amplification is associated with lung inflammation, lung damage, and respiratory distress in patients with severe COVID-19 [6–10, 16], inhibition of terminal complement at the level of C5 may reduce amplification of the inflammatory and hypercoagulation pathways without inhibiting upstream complement pathways, which preserve the innate immune response. Herein, we evaluated whether the modified ravulizumab dosing regimen selected for this study population resulted in terminal complement inhibition in the first 22 patients enrolled in the ravulizumab + BSC treatment group.

In these severe COVID-19 patients, baseline levels of C5 ranged from 106 to 343 µg/mL. These data suggest that compared to healthy individuals whose C5 levels are typically below 100 µg/mL [25], terminal complement levels were elevated in all 22 patients. Three patients had baseline levels of C5 that were similar to those reported in PNH and aHUS, which typically range from 100 to 150 µg/mL [21, 22], whereas 19 patients had levels that were quantitatively higher than those observed in PNH and aHUS (> 150 µg/mL). Variations in baseline terminal complement levels have also been reported in a study of 103 patients hospitalized with COVID-19, in which circulating sC5b-9 levels were significantly elevated in 64% of patients compared to healthy controls [6].

The dosing regimen implemented in this study resulted in ravulizumab concentrations remaining above the threshold of 175 µg/mL, which indicates a near maximal PD effect (complete C5 inhibition), at all measured timepoints including in the two patients at day 22. These data demonstrate that the modified dosing regimen achieved complete terminal complement inhibition with the first dose of ravulizumab and that complete terminal complement inhibition was likely to be sustained for at least 22 days with doses on days 1, 5, 10, and 15. Overall, these PK/PD data support the continued use of this modified dosing regimen in this setting. Analysis of the total study population data will determine the generalizability of these PK/PD results and whether inhibition of terminal complement results in improved clinical outcomes.

Though this evaluation included only 22 patients, baseline characteristics appear to be representative of patients who develop severe COVID-19 with respiratory distress and a need for mechanical ventilation. Patients with severe COVID-19 tend to be elderly, heavier, and have a history of hypertension, cardiovascular disease, or diabetes mellitus [26]. In this analysis, > 30% of patients were over the age of 70 years; and all 22 patients weighed at least 60 kg. A large percentage of patients reported diabetes mellitus, hypertension, hyperlipidemia, or obesity.

Kidney function, liver function, and age have not been shown to affect the PK/PD of ravulizumab in PNH and aHUS [20]. On the basis of the present analysis, which included elderly patients with comorbidities, it is not anticipated that further dose adjustments will be required for patients with severe COVID-19. Although the modified dosing regimen appears to accommodate the augmented complement activation successfully, there may be clinical circumstances, related to COVID-19, which require additional dose adjustments, such as blood transfusions.

Limitations

This PK/PD evaluation does not include clinical outcomes and therefore no inferences about the impact of ravulizumab on the course of disease can be made. The baseline C5 data reported herein suggest an association between severe COVID-19 and terminal complement upregulation, but do not inform whether C5 is a marker of disease severity or a contributor to the pathobiology. In addition, as there is a paucity of data describing C5 levels in viral infections, interpreting baseline C5 levels in the context of infectious disease is difficult. A control group was not included in this analysis; and therefore, inhibition of C5 levels can only be presumed to reflect ravulizumab inhibition of terminal complement. Descriptions of the change in free C5 levels in patients on BSC would be needed to

support this conclusion. In this cohort, no patients weighed < 60 kg. Though additional data are needed, drug exposures are expected to be no lower in patients < 60 kg than those achieved in this evaluation. A full PK/PD characterization using model-based techniques and an outcome analysis of the whole cohort of study ALXN1210-COV-305 are planned.

CONCLUSIONS

These results contribute to the growing body of evidence that suggests that severe COVID-19 is a disease characterized by significant terminal complement amplification [6–10]. In this preliminary PK/PD evaluation of 22 patients with severe COVID-19 enrolled in the ALXN1210-COV-305 phase 3 study, a modified ravulizumab dosing regimen resulted in immediate and complete terminal complement inhibition that could be sustained for up to 22 days. Data from this analysis support the continued use of this dosage regimen in the ongoing phase 3 study.

ACKNOWLEDGEMENTS

not available for two sites). Patients or their legal representative provided written informed consent. If the patient and legal representative were unable to provide informed consent and if local regulations allowed it, exceptions could be granted per the judgement of the investigator or designee. Written certification from the investigator and a physician who was not involved with the research was necessary and needed to be submitted to the IRB (local and central)/independent ethics committee within 5 working days of administration of the initial dose.

Data Availability. All the results pertaining to this analysis are contained in this paper. Once the primary manuscript describing protocol-specified endpoints has been published, Alexion will consider requests for disclosure of clinical study participant-level data provided that participant privacy is assured through methods like data de-identification, pseudonymization, or anonymization (as required by applicable law), and if such disclosure was included in the relevant study informed consent form or similar documentation. Qualified academic investigators may request participant-level clinical data and supporting documents (statistical analysis plan and protocol) pertaining to Alexion-sponsored studies. Further details regarding data availability and instructions for requesting information are available in the Alexion Clinical Trials Disclosure and Transparency Policy at https://alexion.com/our-research/research-and-development. Link to Data Request Form (https://www.alexion.com/contact-alexion/medical-information).

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516.

2. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? JCI Insight. 2020;5(15):e140711.

3. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992 e3-1000 e3.

4. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8.

5. Tiwari R, Mishra AR, Mikaeloff F, et al. In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis. Comput Struct Biotechnol J. 2020;18:3734–44.

6. Peffault de Latour R, Bergeron A, Lengline E, et al. Complement C5 inhibition in patients with COVID-19—a promising target? Haematologica. 2020;105(12):2847–50.

7. Holter JC, Pischke SE, de Boer E, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci USA. 2020;117(40):25018–25.

8. Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588(7836):146–50.

9. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.

10. Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation and endothelial perturbation

parallel COVID-19 severity and activity. J Autoimmun. 2021;116:102560.

11. D'Alessandro A, Thomas T, Dzieciatkowska M, et al. Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level. J Proteome Res. 2020;19(11):4417–27.

12. Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609–15.

13. Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051–63.

14. Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753-18.

15. Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77.

16. Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine. 2020;28:100590.

17. Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–7.

18. Laurence J, Mulvey JJ, Seshadri M, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.

19. Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909.

20. United States Food and Drug Administration. Ultomiris® (ravulizumab-cwvz) prescribing information. Boston: Alexion Pharmaceuticals; 2019.

21. Peffault de Latour R, Brodsky RA, Ortiz S, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020;191(3):476–85.

22. Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287–96.

23. Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S. A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of intravenously administered ravulizumab compared with best supportive care in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):639.

24. Alexion Pharmaceuticals Inc. NDA/BLA multi-disciplinary review and evaluation BLA 761108. Ultomiris (ravulizumab) 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761108Orig1s000MultidisciplineR.pdf. Accessed 30 Oct 2020.

25. Gaya da Costa M, Poppelaars F, van Kooten C, et al. Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population. Front Immunol. 2018;9:2664.

26. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853–62.